Sanity Group Closes $44.2M Series A
June 15th, 2021
Largest European Cannabis Funding Round to Date
BERLIN, June 15, 2021 /PRNewswire/ – Berlin-based cannabis start-up Sanity Group announced today it has closed a $44.2M USD Series A financing round with new investment led by Swiss venture capital firm Redalpine along with US-based Navy Capital and SOJE Capital. GMPVC also participated in the round.
This represents the largest round of cannabis funding in Europe to date and brings total investment in Sanity Group to $73M USD.
An expanding position as a leading cannabis company in Europe
Sanity Group aims to improve people’s quality of life through the use of cannabinoids. In addition to pharmaceuticals, the focus is also on wellbeing and cosmetic products.
The new capital will be used primarily to further expand the Group’s medical division in Europe. Funds will also be used for the build out of EU-GMP-compliant research and production facility new Frankfurt am Main for the entire Group, which will serve both the medical and the wellbeing areas of the Sanity Group in the future, and to expand Sanity Group’s consumer goods business. Sanity Group currently employs 90 employees in Europe including cannabis experts, physicians, pharmacists and biologists.
“A round of this magnitude shows that cannabis is increasingly moving into the mainstream of investor awareness, and represents an important milestone in our business expansion on our way to becoming Europe’s leading cannabis company,” says Finn Age Hänsel, Founder and Managing Director of Sanity Group. “We are very pleased about the trust placed in us by new and existing investors. Our thanks go not only to our new partners, but also to those who have been by our side for a long time and support us on our journey.”
Previous investors include HV Capital, TQ Ventures, Atlantic Food Labs, Cherry Ventures, Calyx, Bitburger Ventures and SevenVentures. In addition, Sanity Group has attracted prominent celebrity angels including music producers will.i.am, Scooter Braun and actress Alyssa Milano.
“Our goal is to leverage the full potential of the cannabis plant and to research and harness the various cannabinoids. We are always on the lookout for partners who can not only support us financially in our endeavors, but above all are a good strategic fit for us. Redalpine’s investments in the life science and medical sector as well as Navy Capital with cannabis portfolio companies in the healthcare and consumer-goods sector ideally complement our existing investor setup and cover the entire range of our business in the health, life science and consumer-goods sector,” adds Sanity Group co-founder and Managing Director Fabian Friede, who founded the company in 2018 together with Finn Hänsel with the aim of providing people in Europe with newly developed cannabinoid-based medicines and health products.
“The European cannabis market faces exciting developments in the coming months. Compared to the North American market, Europe is now where we were in the U.S. about four years ago. We want to bring our expertise and experience to the table. For our first investment in Europe, it was important for us to find a team that understands the market and has real industry experts in its ranks. The Sanity Group team particularly impressed us with their expertise and clear approach,” says Sean Stiefel, CEO at Navy Capital.
About Sanity Group
Sanity Group has set itself the goal of improving people’s quality of life through the sensible use of cannabinoids in Europe. In addition to pharmaceuticals, the focus is also on cannabinoid-based wellbeing and cosmetic products. At the same time, Sanity Group is also working and researching new medical products, innovative dosage forms and technological products and services for the further development of the infrastructure. Sanity Group was founded in 2018 by Finn Age Hänsel and Fabian Friede and now employs a team of over 90 people: at the headquarters in Berlin and the research site near Frankfurt am Main. The Sanity Group brands are Vayamed (pharmaceuticals), VAAY (CBD products) and This Place (functional cosmetics). More information at sanitygroup.com.
Redalpine is a leading European early stage venture capital investor focused on disruptive innovation and with a broad sector investment strategy from health-tech to ICT startups. Redalpine’s diverse team supports the 70+ portfolio companies not only with financial investment but also with its in-house operational and subject matter expertise and extensive international network. Redalpine’s ambition is to help talented entrepreneurs turn their visions into reality and scale their businesses into international success stories.
About Navy Capital
Navy Capital’s research-oriented, fundamentally-driven investment process focuses on identifying attractive opportunities within the Consumer, Healthcare, Technology and Agriculture sectors. Navy Capital invests in publicly traded and private companies that will gain market share over time in their respective verticals.
SOURCE Sanity Group
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.